Summary
In the Canadian/European randomized controlled study on cyclosporin A (CsA) in recent onset Type 1 (insulin-dependent) diabetes, treatment with the immunosuppressive drug had increased and maintained Beta-cell function and clinical remission during the first 12 months. Following discontinuation of the study drug and double-blinding after a mean of 13.8 months former CsA patients doubled the daily insulin dose within 6 months reaching the level of former placebo patients. The difference in Beta-cell function between the two groups was also lost. Metabolic control (HbA1c) was transiently worse in the former CsA group. Adverse effects of cyclosporin A on systolic blood pressure, haemoglobin levels, serum potassium and creatinine levels also remitted during that time. We conclude that treatment with cyclosporin A for a mean of 13.8 months had no long-lasting effect on the course of Type 1 diabetes persisting beyond drug discontinuation.
Article PDF
Similar content being viewed by others
References
Stiller CR, Dupré J, Gent M, Jenner MR, Keown PA, Laupacis A, Martell R, Rodger NW, von Graffenried B, Wolfe BMJ (1984) Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 223: 1362–1367
Feutren G, Papoz L, Assan R, Vialettes B, Karsenty G, Vexiau P Du Rostu H, Rodier M, Sirmai J, Lallemand A, Bach JF (1986) Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Lancet II: 119–123
The Canadian/European Randomized Control Trial Group (1988) Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 37: 1574–1582
Dupré J, Stiller CR, Gent M, Donner A, von Graffenried B, Murphy G, Heinrichs D, Jenner MR, Keown PA, Laupacis A, Mahon J, Martell R, Rodger NW, Wolfe BW (1988) Effects of immunosuppression with cyclosporine in insulin-dependent diabetes mellitus of recent onset: The Canadian open study at 44 months. Transpl Proc XX [Suppl 4]: 184–192
Assan R, Feutren G, Sirmai J (1988) Cyclosporine trials in diabetes: updated results of the French experience. Transpl Proc XX [Suppl 4]: 178–183
Dupré J, Stiller CR, Gent M, Donner A, von Graffenried B, Heinrichs D, Jenner M, Keown P, Mahon J, Martell R, Momah CI, Murphy G, Rodger NW, Wolfe BM (1988) Clinical trials of cyclosporin in IDDM. Diabetes Care 11 [Suppl 1]: 37–44
Andreani D, Kolb H, Pozzilli P (1989) Immunotherapy of type 1 diabetes. John Wiley & Sons, Chichester
Like AA, Dirodi V, Thomas S, Guberski DL, Rossini AA (1984) Prevention of diabetes mellitus in the BB/W rat with cyclosporin-A. Am J Pathol 117: 92–97
Brayman KL, Armstrong J, Barker CF, Naji A (1986) Intermittent cyclosporine administration and prevention of diabetes in the BB rat. Transpl Proc XVIII: 1545–1547
Jaworski MA, Jewell LD, Honore L, Metha JG, Bayens-Simmonds J, McGuire-Clark P, Schouls JJ, Yap WY (1987) Immunosuppression in autoimmune disease: the double-edged sword in BB rat. Clin Invest Med 10: 488–495
Vague P, Vialettes B, Picq R, Dol S, Lassmann-Vague V (1989) Effect of cyclosporin A on B-cell loss in Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 32: 887–888 (Letter)
Feldt-Rasmussen B, Jensen T, Dieperink H, Mandrup-Poulsen T, Nerup J, Bendtzen K, Andersen V, Kemp E, Leyssac PP (1990) Nephrotoxicity of cyclosporin A in patients with newly diagnosed type 1 diabetes mellitus. Diab Med 7: 429–433
Bougneres PF, Carel JC, Castano L, Boitard C, Gardin JP, Landais P, Hors J, Mihatsch MJ, Paillard M, Chaussain JL, Bach JF (1988) Factors associated with early remission of type 1 diabetes in children treated with cyclosporine. N Engl J Med 318: 663–670
Feutren G (1988) Functional consequences and risk factors of chronic cyclosporine nephrotoxicity in type 1 diabetes trials. Transpl Proc XX [Suppl 4]: 356–366
Bougneres PF, Landais P, Boisson C, Carel JC, Frament N, Boitard C, Chaussain JL, Bach JF (1990) Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes 39: 1264
Author information
Authors and Affiliations
Additional information
Prepared by the authors on behalf of The Canadian/European Randomized Control Trial Group (Please see acknowledgements for complete listing).
Rights and permissions
About this article
Cite this article
Martin, S., Schernthaner, G., Nerup, J. et al. Follow-up of cyclosporin A treatment in Type 1 (insulin-dependent) diabetes mellitus: lack of long-term effects. Diabetologia 34, 429–434 (1991). https://doi.org/10.1007/BF00403182
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00403182